Group Eczema Education Visits:Impact on Patient and Family Quality of Life
1 other identifier
interventional
36
1 country
1
Brief Summary
The objective of this study is to determine whether group educational visits improve the quality of life of patients referred to the Dermatology Clinic. Secondary outcomes will be to determine whether group educational visits influences other key elements of patient care such as topical steroid usage, disease exacerbations, emergency visits, and phone calls to the office. Lastly, the investigators hope to evaluate which aspects of the educational visit were found to be the most helpful to families caring for children with atopic dermatitis (AD). Patients will be new atopic dermatitis referrals to OHSU dermatology and pediatric dermatology clinics. All consecutive patients with such appointments during a three month time period will be screened for participation in the study. Parents will be recruited via telephone. In the intervention group, parents will be invited to participate in a group education visit prior to their first appointment with a dermatologist. All parents in the study will fill out questionnaires. The children involved in the study will be assigned an eczema severity score during their routine visits, but this will be incorporated into the regular clinic assessment. The Childhood Atopic Dermatitis Impact Scale (CADIS) assesses the quality of life in households with children who have atopic dermatitis. The Eczema Area and Severity Index (EASI) measures the extent and severity of the patient's atopic dermatitis. The change in CADIS scores will be analyzed to determine if there is a more significant improvement in quality of life for the group in which parents receive the group eczema education visit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2010
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2010
CompletedFirst Submitted
Initial submission to the registry
June 9, 2010
CompletedFirst Posted
Study publicly available on registry
June 14, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
April 13, 2014
CompletedJuly 11, 2019
July 1, 2019
1.3 years
June 9, 2010
July 9, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The difference between the two groups in CADIS score
The primary outcome will be the difference between the two groups in CADIS score as measured at four weeks. CADIS is a validated outcome of pediatric quality of life in AD.
4 weeks
Secondary Outcomes (3)
Assess extent of skin disease.
Between 4 weeks and 4 months of the first visit.
Assess average monthly number of follow-up phone calls.
Between 4 weeks and 4 months of the first visit.
Assess average monthly number of urgent and emergency visits.
Between 4 weeks and 4 months of the first visit.
Study Arms (2)
Group eczema education session
ACTIVE COMPARATOROne group will attend a group eczema education session. All subjects will answer quality of life questions two times.
Control group
ACTIVE COMPARATORThe other group will not attend the group eczema education session. Both groups will be asked quality of life questions two times.
Interventions
Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
The control group will not attend the group eczema education session.
Eligibility Criteria
You may qualify if:
- Children ages 2 months though 6 years.
- Participants must carry a diagnosis of atopic dermatitis according to the Hanifin and Rajka criteria.
- New patients or consultations at an OHSU clinic.
- English-speaking families will be included in this study
You may not qualify if:
- Subjects who have been on systemic therapies for treatment of their atopic dermatitis (prednisone or cyclosporine)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Oregon Health & Science University
Portland, Oregon, 97239, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Susan J. Tofte, FNP-C
Oregon Health and Science University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 9, 2010
First Posted
June 14, 2010
Study Start
May 1, 2010
Primary Completion
August 1, 2011
Study Completion
April 13, 2014
Last Updated
July 11, 2019
Record last verified: 2019-07